This research report provides a comprehensive analysis of the Oncolytic Virus Cancer Immunotherapy market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Oncolytic Virus Cancer Immunotherapy market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Oncolytic Virus Cancer Immunotherapy, challenges faced by the industry, and potential opportunities for market players.
The global Oncolytic Virus Cancer Immunotherapy market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Oncolytic Virus Cancer Immunotherapy market presents opportunities for various stakeholders, including Lung Cancer, Breast Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Oncolytic Virus Cancer Immunotherapy market. Additionally, the growing consumer demand present avenues for market expansion.
The global Oncolytic Virus Cancer Immunotherapy market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.
Key Features:
The research report on the Oncolytic Virus Cancer Immunotherapy market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Oncolytic Virus Cancer Immunotherapy market.
Market Overview: The report provides a comprehensive overview of the Oncolytic Virus Cancer Immunotherapy market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Monoclonal Antibodies, Checkpoint Inhibitors), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Oncolytic Virus Cancer Immunotherapy market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Oncolytic Virus Cancer Immunotherapy market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Oncolytic Virus Cancer Immunotherapy market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Oncolytic Virus Cancer Immunotherapy market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Oncolytic Virus Cancer Immunotherapy market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Oncolytic Virus Cancer Immunotherapy market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Oncolytic Virus Cancer Immunotherapy, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Oncolytic Virus Cancer Immunotherapy market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Oncolytic Virus Cancer Immunotherapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
Market segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
Global Oncolytic Virus Cancer Immunotherapy Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oncolytic Virus Cancer Immunotherapy, market overview.
Chapter 2: Global Oncolytic Virus Cancer Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Oncolytic Virus Cancer Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oncolytic Virus Cancer Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Oncolytic Virus Cancer Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oncolytic Virus Cancer Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oncolytic Virus Cancer Immunotherapy Overall Market Size
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size: 2023 VS 2030
2.2 Global Oncolytic Virus Cancer Immunotherapy Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oncolytic Virus Cancer Immunotherapy Players in Global Market
3.2 Top Global Oncolytic Virus Cancer Immunotherapy Companies Ranked by Revenue
3.3 Global Oncolytic Virus Cancer Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Oncolytic Virus Cancer Immunotherapy Companies in Global Market, by Revenue in 2023
3.5 Global Companies Oncolytic Virus Cancer Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oncolytic Virus Cancer Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 Oncolytic Virus Cancer Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Oncolytic Virus Cancer Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Oncolytic Virus Cancer Immunotherapy Market Size Markets, 2023 & 2030
4.1.2 Monoclonal Antibodies
4.1.3 Checkpoint Inhibitors
4.1.4 Oncoloytic Viral Therapies and Cancer Vaccines
4.2 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2024
4.2.2 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2025-2030
4.2.3 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oncolytic Virus Cancer Immunotherapy Market Size, 2023 & 2030
5.1.2 Lung Cancer
5.1.3 Breast Cancer
5.1.4 Colorectal Cancer
5.1.5 Melanoma
5.1.6 Prostate Cancer
5.1.7 Head and neck Cancer
5.1.8 Ovarian Cancer
5.1.9 Pancreatic Cancer
5.1.10 Others
5.2 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2024
5.2.2 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2025-2030
5.2.3 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Oncolytic Virus Cancer Immunotherapy Market Size, 2023 & 2030
6.2 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2024
6.2.2 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2025-2030
6.2.3 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.3.2 US Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.3.3 Canada Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.3.4 Mexico Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.4.2 Germany Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.3 France Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.4 U.K. Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.5 Italy Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.6 Russia Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.7 Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.8 Benelux Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.5.2 China Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.3 Japan Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.4 South Korea Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.5 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.6 India Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.6.2 Brazil Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.6.3 Argentina Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.7.2 Turkey Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7.3 Israel Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7.4 Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7.5 UAE Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
7 Oncolytic Virus Cancer Immunotherapy Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.1.4 AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.2.4 Amgen Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.2.5 Amgen Key News & Latest Developments
7.3 F Hoffman-La Roche
7.3.1 F Hoffman-La Roche Company Summary
7.3.2 F Hoffman-La Roche Business Overview
7.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.3.4 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.3.5 F Hoffman-La Roche Key News & Latest Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Company Summary
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.4.4 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.4.5 Bristol-Myers Squibb Key News & Latest Developments
7.5 Novartis AG
7.5.1 Novartis AG Company Summary
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.5.4 Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.5.5 Novartis AG Key News & Latest Developments
7.6 Merck & Co., Inc.
7.6.1 Merck & Co., Inc. Company Summary
7.6.2 Merck & Co., Inc. Business Overview
7.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.6.4 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.6.5 Merck & Co., Inc. Key News & Latest Developments
7.7 Pfizer
7.7.1 Pfizer Company Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.7.4 Pfizer Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.7.5 Pfizer Key News & Latest Developments
7.8 Biovex
7.8.1 Biovex Company Summary
7.8.2 Biovex Business Overview
7.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.8.4 Biovex Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.8.5 Biovex Key News & Latest Developments
7.9 Cell Genesys
7.9.1 Cell Genesys Company Summary
7.9.2 Cell Genesys Business Overview
7.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.9.4 Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.9.5 Cell Genesys Key News & Latest Developments
7.10 Crusade Laboratories
7.10.1 Crusade Laboratories Company Summary
7.10.2 Crusade Laboratories Business Overview
7.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.10.4 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.10.5 Crusade Laboratories Key News & Latest Developments
7.11 Genelux Corporation
7.11.1 Genelux Corporation Company Summary
7.11.2 Genelux Corporation Business Overview
7.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.11.4 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.11.5 Genelux Corporation Key News & Latest Developments
7.12 Lokon Pharma
7.12.1 Lokon Pharma Company Summary
7.12.2 Lokon Pharma Business Overview
7.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.12.4 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.12.5 Lokon Pharma Key News & Latest Developments
7.13 MultiVir
7.13.1 MultiVir Company Summary
7.13.2 MultiVir Business Overview
7.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.13.4 MultiVir Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.13.5 MultiVir Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Oncolytic Virus Cancer Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Oncolytic Virus Cancer Immunotherapy Market Drivers in Global Market
Table 3. Oncolytic Virus Cancer Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Oncolytic Virus Cancer Immunotherapy in Global Market
Table 5. Top Oncolytic Virus Cancer Immunotherapy Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Oncolytic Virus Cancer Immunotherapy Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Companies, 2019-2024
Table 8. Global Companies Oncolytic Virus Cancer Immunotherapy Product Type
Table 9. List of Global Tier 1 Oncolytic Virus Cancer Immunotherapy Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oncolytic Virus Cancer Immunotherapy Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 32. AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Amgen Company Summary
Table 35. Amgen Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 36. Amgen Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 37. Amgen Key News & Latest Developments
Table 38. F Hoffman-La Roche Company Summary
Table 39. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 40. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 41. F Hoffman-La Roche Key News & Latest Developments
Table 42. Bristol-Myers Squibb Company Summary
Table 43. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 44. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 45. Bristol-Myers Squibb Key News & Latest Developments
Table 46. Novartis AG Company Summary
Table 47. Novartis AG Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 48. Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 49. Novartis AG Key News & Latest Developments
Table 50. Merck & Co., Inc. Company Summary
Table 51. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 52. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 53. Merck & Co., Inc. Key News & Latest Developments
Table 54. Pfizer Company Summary
Table 55. Pfizer Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 56. Pfizer Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 57. Pfizer Key News & Latest Developments
Table 58. Biovex Company Summary
Table 59. Biovex Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 60. Biovex Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 61. Biovex Key News & Latest Developments
Table 62. Cell Genesys Company Summary
Table 63. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 64. Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 65. Cell Genesys Key News & Latest Developments
Table 66. Crusade Laboratories Company Summary
Table 67. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 68. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 69. Crusade Laboratories Key News & Latest Developments
Table 70. Genelux Corporation Company Summary
Table 71. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 72. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 73. Genelux Corporation Key News & Latest Developments
Table 74. Lokon Pharma Company Summary
Table 75. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 76. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 77. Lokon Pharma Key News & Latest Developments
Table 78. MultiVir Company Summary
Table 79. MultiVir Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 80. MultiVir Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 81. MultiVir Key News & Latest Developments
List of Figures
Figure 1. Oncolytic Virus Cancer Immunotherapy Segment by Type in 2023
Figure 2. Oncolytic Virus Cancer Immunotherapy Segment by Application in 2023
Figure 3. Global Oncolytic Virus Cancer Immunotherapy Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2023
Figure 8. By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 9. By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 10. By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 12. By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 14. By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 15. By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 16. US Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 20. Germany Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 21. France Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 28. China Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 32. India Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 34. Brazil Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 37. Turkey Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 41. AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Amgen Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Pfizer Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Biovex Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. MultiVir Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
